Kuangli Bio Tech Holdings Co Ltd

Kuangli Bio Tech's capital structure shows a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.36, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -9.32 million TWD, and operating cash flow is also negative at -145.33 million TWD, signaling cash flow constraints. Profitability metrics are weak, with a return on equity of -33.42% and a return on assets of -16.25%. These figures fall significantly below the industry median for the Personal Products sector, which typically sees positive returns. The company reported a net loss of 192.98 million TWD and an operating loss of 165.87 million TWD, indicating a challenging operating environment. Geographically, Kuangli Bio Tech distributes its products in the domestic market and to overseas markets such as Mainland China and Korea. However, the financial data does not provide a breakdown of revenue by region, making it difficult to assess geographic concentration risk. The company's exposure to international markets may be subject to trade tensions and currency fluctuations. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Historical revenue data shows a total of 377.03 million TWD, but without prior period comparisons, it is difficult to assess growth trends. The negative operating and net income suggest a need for operational improvements or cost reductions to achieve profitability. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's capital structure and cash flow challenges may limit its ability to invest in growth opportunities or withstand economic downturns. Recent events and filings have not been disclosed in the provided data, so there is no information on recent strategic moves, management changes, or regulatory actions that could impact the company's performance. Investors should monitor any upcoming filings for insights into the company's strategic direction and financial health.